• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Yael Mosse, Megan S. Lim, +11 authors Susan M. Blaney
  • Medicine
  • The Lancet. Oncology
  • 2013 (First Publication: 1 May 2013)
  • BACKGROUND Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumours, non-small-cellExpand
  • Stacey L Berg, Susan M. Blaney, +10 authors Michael Brennan Harris
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2005 (First Publication: 20 May 2005)
  • PURPOSE Nelarabine (compound 506U78), a water soluble prodrug of 9-b-d-arabinofuranosylguanine, is converted to ara-GTP in T lymphoblasts. We sought to define the response rate of nelarabine inExpand
  • Martin A. Champagne, Renaud Capdeville, +7 authors Mark Bernstein
  • Medicine
  • Blood
  • 2004 (First Publication: 1 November 2004)
  • The purpose of this study was to determine dose-limiting toxicities and pharmacokinetics of imatinib in children with refractory or recurrent Philadelphia chromosome-positive (Ph(+)) leukemias. OralExpand
  • Julia L Glade Bender, Peter C Adamson, +13 authors Darrell J. Yamashiro
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2008 (First Publication: 20 January 2008)
  • PURPOSE We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)-neutralizing antibody bevacizumab (BV). Primary aims included estimating the maximum-tolerated doseExpand
  • Elizabeth Fox, Bassem I. Razzouk, +8 authors Peter C Adamson
  • Medicine
  • Blood
  • 2008 (First Publication: 15 January 2008)
  • Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL). We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) withExpand
  • Richard Aplenc, Susan M. Blaney, +7 authors Peter C Adamson
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2011 (First Publication: 1 March 2011)
  • UNLABELLED PURPOSE Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases, BCR-ABL, c-KIT, EPHA2, and the PDGF-β receptor. Dasatinib wasExpand